Novartis Clozaril “Dear Doctor” letter
Executive Summary
Novartis issues "Dear Health Care Provider" letter April 1 on the diabetes class warning for atypical antipsychotics. Novartis added class warning to Clozaril (clozapine) labeling Dec. 23. AstraZeneca (Seroquel), Lilly (Zyprexa) and Bristol-Myers Squibb (Abilify) issued similar letters (1"The Pink Sheet" April 5, 2004, p. 32). FDA requested that sponsors revise labeling in September 2003 (2"The Pink Sheet" Sept. 22, 2003, p. 20)...
You may also be interested in...
Bristol Diabetes Class Warning For Abilify Cites “Paucity” Of Reports
Bristol-Myers Squibb's Abilify now carries a diabetes class warning for atypical antipsychotics, although the company plans to continue discussions with FDA about modifications as new data become available
FDA Sides With Lilly; Seeks Class Warning On Antipsychotic Diabetes Risk
The comparative risk for diabetes among atypical antipsychotics needs further research, FDA says in a letter to six manufacturers requesting a diabetes and hyperglycemia warning across the class
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.